|By Marketwired .||
|December 13, 2010 12:21 PM EST||
LAVAL, QUEBEC -- (Marketwire) -- 12/13/10 -- Warnex Inc. (TSX: WNX) announced today that it has signed a Contribution Agreement with the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP), for forensic DNA analysis of "Touch DNA" samples from expended firearm cartridges. The research will be performed by Warnex's PRO-DNA Services division located in Thunder Bay, Ontario.
"We are pleased to obtain this funding from NRC-IRAP, which will allow us to improve methods for analyzing Touch DNA and hence broaden our capabilities in forensic testing," said Mark Busgang, President and CEO of Warnex. "These methods can assist in the DNA identification of a criminal even if the only available evidence is a simple bullet casing. They can also be applied to a variety of other types of forensic evidence, such as samples from door knobs, steering wheels or utensils."
Touch DNA testing refers to the DNA analysis of skin cells left on an object, such as firearm cartridges or bullets, after a person has touched it. Analysis of Touch DNA poses many challenges. Touch DNA samples are not visible and since they contain smaller amounts of DNA than found in other types of evidence, it is more difficult to obtain DNA profiles from these samples. Warnex will use nuclear and mitochondrial DNA techniques to improve the analysis of Touch DNA samples.
In addition to technical and business advisory services, NRC-IRAP will contribute up to $47,300 for the research and development work performed by Warnex.
Warnex PRO-DNA services is the only private laboratory in Canada providing STR, Y-STR, miniSTR, and mitochondrial DNA testing services for forensic and parentage testing purposes. Mitochondrial DNA testing is crucial in cases where nuclear DNA testing is not possible such as for shed hairs at crime scenes, identification of missing persons (skeletal remains with degraded DNA), and when there is insufficient nuclear DNA.
Warnex PRO-DNA Services is accredited by the Standards Council of Canada (SCC) as a DNA testing laboratory for forensics, parentage and other familial relationships under ISO 17025/CAN-P-4E and CAN-P-1578, as well as the American Society of Crime Lab Directors/Laboratory Accreditation Board - International® (ASCLD/LAB-International®) for forensic science testing.
Warnex offers its forensic services to law enforcement, lawyers, investigators and private clients worldwide. For more information on Warnex's forensic and DNA identification services, visit www.prodna.ca.
Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex Analytical Services provides pharmaceutical and biotechnology companies with a variety of quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex Bioanalytical Services specializes in bioequivalence and bioavailability studies for clinical trials. Warnex Medical Laboratories provides specialized testing for the healthcare industry as well as pharmaceutical and central laboratory services. Warnex PRO-DNA Services offers DNA identification tests for paternity, maternity and other family relationships, as well as for immigration and forensic testing purposes. Warnex has three facilities located in Laval and Blainville, Quebec, and Thunder Bay, Ontario.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, liquidity risk, key customers and business partners, credit risk, foreign currency risk, government regulations, laboratory facilities, volatility of share price, employees, suppliers, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.